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Abstract
Cancer	stem	cells	(CSCs)	play	an	important	role	in	cancer	treatment	resistance	and	
disease	progression.	 Identifying	an	effective	anti‐CSC	agent	may	 lead	 to	 improved	
disease	control.	We	used	CSC‐associated	gene	signatures	to	identify	drug	candidates	
that	may	 inhibit	CSC	growth	by	 reversing	 the	CSC	gene	signature.	Thiostrepton,	a	
natural	 cyclic	 oligopeptide	 antibiotic,	was	 the	 top‐ranked	 candidate.	 In	 non–small‐
cell	 lung	 cancer	 (NSCLC)	 cells,	 thiostrepton	 inhibited	 CSC	 growth	 in	 vitro	 and	 re‐
duced	protein	expression	of	cancer	stemness	markers,	including	CD133,	Nanog	and	
Oct4A.	In	addition,	metastasis‐associated	Src	tyrosine	kinase	signalling,	cell	migration	
and	 epithelial‐to‐mesenchymal	 transition	 (EMT)	were	 all	 inhibited	 by	 thiostrepton.	
Mechanistically,	thiostrepton	treatment	led	to	elevated	levels	of	tumour	suppressor	
miR‐98.	Thiostrepton	combined	with	gemcitabine	synergistically	suppressed	NSCLC	
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1  | INTRODUC TION
Lung	cancer	is	the	leading	cause	of	cancer‐related	death	worldwide.1 
The	 five‐year	 survival	 rate	 is	 approximately	18%	 for	patients	with	
lung	cancer	and	3.9%	for	those	with	advanced	stages2	of	the	disease,	
lower	 than	 the	 survival	 rates	 for	 colon	 (65%),	 female	breast	 (90%)	
and	prostate	(99%)	cancers.3	Non–small‐cell	lung	cancer	(NSCLC)	ac‐
counts	for	approximately	85%	of	all	lung	cancers.	Chemotherapies,	
including	pemetrexed	or	gemcitabine	in	combination	with	platinum,	
are	frequently	used	as	the	first‐line	therapy	for	advanced	NSCLC.4‐6 
However,	current	chemotherapy	regimens	do	not	provide	long‐term	
disease	control	in	most	patients	with	NSCLC.7,8	Those	who	receive	
chemotherapy	 eventually	 encounter	 drug	 resistance	 and	 disease	
progression.9,10	 Alternative	 therapeutic	 strategies	 are	 urgently	
needed.
Cancer	stem	cells	(CSCs)	play	an	important	role	in	cancer	recur‐
rence,	 progression	 and	 drug	 resistance.11‐13	 Lung	 CSCs	were	 first	
identified	as	CD133+	cells14	and	isolated	in	established	NSCLC	cell	
lines,15,16	forming	floating	spheres	 in	serum‐free	conditions.	These	
CD133+	lung	cancer	spheres	exhibited	self‐renewal	abilities,	stress/
drug	resistance,	epithelial‐to‐mesenchymal	(EMT)	potential	and	the	
ability	 to	 recapitulate	 tumour	 heterogeneity	 in	 vivo.14‐18	 The	 drug	
resistance	may	be	due	to	features	related	to	the	stem	cell	pathway,	
expression	of	high‐level	ATP‐binding	cassette	transporters	and	spe‐
cific	surface	biomarkers.19	Identifying	agents	to	eliminate	CSCs	has	
become	an	important	issue	for	anti‐cancer	drug	development.
Developing	an	entirely	new	drug	is	expensive	and	time‐consum‐
ing.	Drug	repurposing	offers	an	alternative	strategy	for	anti‐cancer	
drug	development,	which	requires	analysing	biological	and	medical	
information	 for	 a	 huge	 number	 of	 drugs.20	 The	Connectivity	Map	
(CMap,	 http://www.broad.mit.edu/cmap/),21	 which	 stores	 expres‐
sion	profiles	 of	 diseases,	 genes	 and	 chemicals,	 provides	 a	 tool	 for	
making	 inferences	based	on	a	query	 and	 the	 internal	profiles.	We	
hypothesized	that	drugs	with	 the	ability	 to	 reverse	the	expression	
of	CSC‐like	gene	signatures	may	inhibit	CSC	growth	and	could	prove	
beneficial	in	the	treatment	of	lung	cancer.	We	tested	the	top‐ranked	
agent	 identified	 by	CMap	 for	 reversing	 potential	CSC	 gene	 signa‐
tures	for	anti‐CSC	abilities	in	vitro	and	in	vivo.	The	synergistic	effect	
of	identified	agents	and	existing	chemotherapies	on	tumour	growth	
inhibition	was	also	examined.
Thiostrepton,	a	macrocyclic	thiopeptide	antibiotic,	belongs	to	the	
thiopeptide	 family	 of	 highly	modified	macrocyclic	 peptides,	which	
are	 produced	 as	 secondary	 metabolites	 by	 actinomycetes	 of	 the	
genus	Streptomyces.22	Thiostrepton	interacts	directly	with	forkhead	
box	M1	 (FOXM1)	and	 inhibits	binding	with	genomic	 target	sites.23 
Thiostrepton	also	 inhibits	growth	and	 induces	apoptosis	 in	human	
cancer	 cells	 by	 inhibiting	 FOXM1	 expression.24	 Based	 on	 CMap	
analysis,	we	identified	thiostrepton	as	a	candidate	to	be	an	anti‐CSC	
agent.	We	 also	 provided	 evidence	 that	 thiostrepton	 can	 suppress	
cancer	cell	proliferation,	migration	and	CSC‐like	properties	in	vitro,	
as	well	as	inhibit	tumorigenesis	in	vivo.	More	importantly,	thiostrep‐
ton	combined	with	gemcitabine	inhibited	NSCLC	cell	growth	syner‐
gistically.	Collectively,	our	findings	suggest	thiostrepton	can	serve	as	
an	anti‐CSC	drug	and	play	a	beneficial	role	in	lung	cancer	treatment.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and chemicals
A549,	 NCI‐H441	 and	 CL141	 are	 lung	 adenocarcinoma	 cell	 lines	
with	wild‐type	EGFR.	CL152	is	a	lung	squamous	carcinoma	cell	line.	
H1299	is	an	NSCLC	cell	 line,	and	H460	is	large	cell	 lung	carcinoma	
cell	line.	A549‐ON	cells	are	A549	cells	co‐overexpressed	Oct‐4A	and	
Nanog.25	H460	cells	were	infected	by	a	CD133	P1	promoter‐driven	
GFP	 reporter	 lentivirus	 and	 cultured	 in	 RPMI‐1640	 supplemented	
with	10%	foetal	bovine	serum	(FBS)	 (GIBCO).26	CD133+GFP+H460	
cells	were	sorted	by	using	a	FACSAria	cell	sorter	 (BD	Biosciences).	
The	other	cell	 lines	were	maintained	 in	RPMI	medium	and	supple‐
mented	with	 10%	 FBS	 (GIBCO),	 2	mmol/L	 l‐glutamine,	 100	U/mL	
penicillin	and	100	μg/mL	streptomycin	(GIBCO).	For	cell	culture	ex‐
periments,	a	10	mmol/L	thiostrepton	stock	solution	was	dissolved	in	
dimethyl	sulfoxide	(DMSO;	Sigma).	Pemetrexed,	gefitinib	and	gemcit‐
abine	were	purchased	from	LC	Laboratories,	while	thiostrepton	and	
cisplatin	were	acquired	from	Sigma	and	Selleckchem,	respectively.
2.2 | L1000 expression profiling
Gene	 expression	 profiles	were	 obtained	 from	 cancer	 cells	 treated	
with	 perturbagens,	 including	 small	 molecules	 and	 Chinese	 herbal	
medicines,	 in	 triplicate	 for	 6	 hours,	 followed	 by	 L1000	 expres‐
sion	profiling21,27	by	Genometry	 Inc	 In	brief,	cells	were	 lysed	after	
6	hours	of	treatment	in	triplicate,	and	mRNA	transcripts	from	whole	
cell	 lysates	were	 rapidly	 captured	 by	 oligo‐dT.	 The	 cDNAs	 gener‐
ated	 by	 reverse	 transcription	 from	mRNA	were	 amplified	 through	
cell	growth	and	induced	apoptosis.	The	inhibition	of	NSCLC	tumours	and	CSC	growth	
by	thiostrepton	was	also	demonstrated	in	vivo.	Our	findings	indicate	that	thiostrep‐
ton,	an	established	drug	identified	in	silico,	is	an	inhibitor	of	CSC	growth	and	a	poten‐
tial	enhancer	of	chemotherapy	in	NSCLC.
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ligation‐mediated	polymerase	chain	reaction	(PCR).	The	PCR	ampli‐
con	was	then	hybridized	to	bar‐coded	Luminex	beads	to	display	the	
expression	values	of	specific	genes.	The	cDNA	was	annealed	with	
specific	probes	for	978	landmark	genes.	A	list	of	overexpressed	and	
underexpressed	probe	sets	was	obtained	using	a	t	test	rank	order.
2.3 | Connectivity scoring by gene set enrichment 
analysis using CMap
Intensity	values	of	gene	expression	profiles	were	first	converted	
to	 robust	 z‐scores	 using	 the	 l1ktools	 downloaded	 from	 the	
CMap/Library	 of	 Integrated	 Network‐based	 Cellular	 Signatures	
(LINCS)	project	of	the	NIH	Common	Fund	programme.	Integrated	
Network‐based	Cellular	Signatures	has	been	replaced	by	the	CLUE	
platform	as	of	February,	2017.	The	new	analytical	tool	can	be	ac‐
cessed	from	https	://clue.io.	A	Perl	script	was	used	to	calculate	the	
connectivity	 score	 for	 each	 gene	 expression	 profile	 against	 the	
anti‐CSC	 or	 CSC	 gene	 signature.21	 The	 anti‐CSC	 gene	 signature	
was	 identified	using	GEO2R	for	differentially	expressed	genes	 in	
the	study	of,	 for	example,	 the	Gene	Expression	Omnibus28	 gene	
signature	GSE18150.29
The	 11	 641	 profiles	 in	 our	 collection	were	 ranked	 by	 connec‐
tivity	 scores	and	used	as	 the	 input	of	 the	 ranking	matrix	 for	gene	
set	 enrichment	 analysis	 (GSEA).	 Thiostrepton	 profiles	 (including	
repeats	and	treatments	 in	different	cancer	cells)	were	grouped	to‐
gether	and	used	as	the	input	gene	set	for	GSEA	to	map	the	ranking	
matrix	and	calculate	the	enrichment	scores.	Normalized	enrichment	
scores	were	obtained	from	1000	permutations	of	gene	sets.	Some	
of	the	gene	signatures	(eg	GSE1893130)	were	obtained	as	CSC	gene	
signatures.	We	scored	the	negative	enrichment.	Finally,	for	CMap/
LINCS	 analysis,	 the	 query‐gene	 signature	was	 uploaded	 to	 LINCS	
Web	Apps	to	obtain	score_best4	scores	of	the	perturbagens	in	the	
database.
2.4 | Colony formation assay
Non–small‐cell	lung	cancer	cells	were	seeded	in	6‐well	plates	at	a	
density	of	600	cells	per	well	and	cultured	for	14	days.	Thiostrepton	
was	added	24	hours	after	seeding.	The	culture	medium	with	thi‐
ostrepton	was	 renewed	every	4	days.	Following	 the	 treatments,	
cells	 were	 washed	 with	 phosphate‐buffered	 saline	 (PBS),	 and	
the	colonies	were	fixed	 in	a	methanol‐acetic	acid	 fixing	solution	
with	 a	 ratio	of	3:1	 and	 stained	with	0.5%	crystal	 violet	 solution	
in	methanol.	After	carefully	 removing	 the	crystal	violet	 solution	
and	rinsing	with	 tap	water,	 the	colonies	were	counted	manually.	
Each	 experiment	 was	 performed	 independently,	 in	 triplicate,	 at	
least	twice.
2.5 | Cytotoxicity assay and drug 
combination analysis
Cells	were	seeded	 in	96‐well	plates	at	a	density	of	2000	cells	per	
well	 in	 triplicate.	 The	 cells	were	 treated	with	 indicated	 agents	 for	
48	hours	on	the	second	day	to	ensure	adequate	plating	efficiency	
and	cell	vitality.	Cells	were	treated	with	different	concentrations	of	
thiostrepton,	pemetrexed,	 cisplatin,	 gemcitabine	and	gefitinib	or	 a	
non‐fixed‐ratio	combination	of	thiostrepton	and	one	of	the	anti‐can‐
cer	agents.
The	cytotoxicity	was	assessed	by	using	a	sulforhodamine	B	(SRB)	
assay.31	Briefly,	 the	medium	was	discarded,	and	the	adherent	cells	
were	fixed	with	100	μL	of	cold	10%	trichloroacetic	acid	(w/v)	in	each	
well	for	1	hour	at	4°C.	Cells	were	stained	after	fixing	with	100	μL/
well	of	0.4%	(w/v,	in	1%	acetic	acid)	SRB	solution	for	30	minutes	at	
room	temperature	and	then	washed	five	times	with	1%	acetic	acid.	
After	air‐drying,	100	μL	of	10	mmol/L	Tris	base	was	added	to	each	
well	and	the	absorbance	was	read	at	546	nm.	Cytotoxicity	was	de‐
fined	 as	 the	 percentage	 of	 cells	 in	 the	 drug‐treated	wells	 relative	
to	the	cell	numbers	in	the	solvent‐only	control	(set	to	100%).	Each	
experiment	 was	 performed	 independently,	 in	 triplicate,	 at	 least	
twice,	and	the	cytotoxicity	was	presented	as	the	mean	±	standard	
deviation.
The	 synergy	 associated	 with	 inducing	 cytotoxicity	 among	 dif‐
ferent	 drug	 combinations	 was	 evaluated	 by	 analysis	 of	 the	 me‐
dian‐dose	effect	and	calculation	of	the	combination	index	(CI)	using	
commercially	 available	 software	 of	 Chou	 and	 Talalay	 software	
(CompuSyn).32,33	According	 to	 the	 recommendations	of	 this	meth‐
odology,	CI	values	of	 less	or	greater	than	1	indicated	synergism	or	
antagonism,	respectively.	A	value	of	1	indicated	an	additive	effect.
2.6 | Cell migration assay
Cell	culture	inserts	(Millipore)	were	placed	in	24‐well	plates.	Serum‐
starved	cells	 (2	×	105	cells)	were	seeded	in	the	upper	chambers	of	
the	 transwell	with	200	μL	of	 serum‐free	medium,	 in	 the	presence	
of	the	vehicle	(DMSO)	or	thiostrepton	(5	μmol/L).	The	lower	cham‐
bers	were	 filled	with	 750	μL	 of	medium	 containing	 10%	FBS	 as	 a	
chemo‐attractant.	After	incubation	for	16	hours,	cells	were	fixed	in	
4%	formaldehyde	and	stained	with	GIEMSA	(Sigma).	After	washing,	
the	non‐penetrating	cells	on	the	inner	surfaces	of	the	upper	cham‐
bers	were	wiped	off	with	cotton	swabs.	The	penetrated	cells	were	
photographed	and	counted	using	a	light	microscope.	Each	assay	was	
performed	in	triplicate.
2.7 | Immunoblotting
After	 treatments,	 cells	 were	 lysed	 in	 a	 lysis	 buffer.	 Total	 pro‐
tein	 contents	were	 isolated	 and	 subjected	 to	 SDS	 polyacrylamide	
gel	 electrophoresis	 and	 electro‐transferred	 onto	 polyvinylidene	
fluoride	 membranes	 (Millipore).	 Immunoblotting	 was	 performed	
using	 primary	 antibodies,	 including	 β‐catenin	 (Cell	 Signaling	
Technology),	c‐Myc	(Cell	Signaling	Technology),	CD44	(Cell	Signaling	
Technology),	 CD133	 (GeneTex),	 Oct‐4A	 (GeneTex),	 Sox2	 (Cell	
Signaling	 Technology),	 FOXM1	 (Abcam),	 E‐cadherin	 (Cell	 Signaling	
Technology),	 Src	 (Cell	 Signaling	 Technology),	 phosphorylated	
Src	 (Tyr416,	 Cell	 Signaling	 Technology),	 caspase‐8	 (Cell	 Signaling	
Technology),	caspase‐9	(Cell	Signaling	Technology),	caspase‐3	(Cell	
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Signaling	Technology)	and	cleaved	PARP	(Cell	Signaling	Technology).	
GAPDH	 (Cell	 Signaling	 Technology),	 α‐tubulin	 (Cell	 Signaling	
Technology)	or	β‐actin	(GeneTex)	acted	as	an	internal	control.	Protein	
detection	was	performed	by	using	an	enhanced	chemiluminescence	
(ECL™)	method	and	the	Luminescence	Imaging	System	(LAS‐4000™,	
Fuji	Photo	Film	Co.,	Ltd).
2.8 | Assays for cancer stemness characteristics
The	assay	of	ALDH1	activity	is	frequently	used	to	define	lung	can‐
cer	stem	cell	populations.34	Aldefluor	assays	were	performed	ac‐
cording	to	the	manufacturer's	guidelines	(StemCell	Technologies).	
Briefly,	 a	 single	 cell	 suspension	 obtained	 from	 cell	 cultures	 was	
incubated	in	Aldefluor	assay	buffer	containing	an	ALDH	substrate	
(bodipy‐aminoacetaldehyde,	 BAAA)	 for	 50	 minutes	 at	 37°C.	 As	
a	 negative	 control,	 a	 fraction	 of	 cells	 from	 each	 sample	was	 in‐
cubated	 under	 identical	 conditions	 in	 the	 presence	 of	 an	 ALDH	
inhibitor	(diethylaminobenzaldehyde,	DEAB).	Flow	cytometry	was	
used	to	detect	the	ALDH‐positive	cell	population.
A	 tumour	 sphere	 formation	 assay	was	 carried	 out	 to	 evaluate	
cancer	stemness.	Lung	cancer	cells	were	seeded	in	6‐well	ultralow‐
attachment	plates	 (Corning	 Inc)	at	a	density	of	2000	cells/mL	 in	a	
serum‐deprived	 culture	medium	consisting	of	DMEM/F12	 supple‐
mented	with	1%	N2	Supplement	(GIBCO),	20	ng/mL	basic	fibroblast	
growth	factor	(Sigma),	20	ng/mL	epidermal	growth	factor	(GIBCO),	
100	U/mL	penicillin	and	100	μg/mL	streptomycin	(GIBCO)	at	37°C	
in	a	humidified	atmosphere	of	95%	air	and	5%	CO2.	Tumour	spheres	
were	counted	after	harvest	using	a	Countess™	(GIBCO)	automated	
cell	counter.
2.9 | Quantitative PCR analyses and 
microRNA assays
All	RNA‐related	experiments	were	performed	by	using	kits	purchased	
from	QIAGEN	(Taiwan)	and	following	the	instructions	provided	by	the	
vendor.	 Total	 RNA	was	 isolated,	 quantified	 and	 reverse	 transcribed	
into	cDNA.	The	primers	of	different	microRNAs	tested	in	this	study	for	
microRNA	quantitative	real‐time	PCR	assays	were	also	purchased	from	
QIAGEN.	 Up‐regulation	 and	 down‐regulation	 of	 miRNAs	 were	 per‐
formed	by	transfecting	cells	with	miRNA	precursors	or	anti‐miRNAs,	
respectively.	 Fifty	 nanomoles	 of	miScript	mimic	 and	 inhibitors	were	
transfected	into	lung	cancer	cells	by	using	the	lipofectamine	2000	rea‐
gent	(Thermo	Fisher	Scientific).	Total	RNA	and	protein	were	isolated	
48	hours	after	treatments	to	determine	the	effects	on	target‐protein	
expression	profiles.
2.10 | Examination of anti‐lung cancer effects 
mediated by thiostrepton in vivo
The	inhibitory	effect	of	thiostrepton	on	tumour	growth	was	evaluated	
by	using	a	mouse	subcutaneous	tumour	xenograft	model.	Human	lung	
adenocarcinoma	 cells	 (NCI‐H441,	 purchased	 from	 ATCC)	 were	 in‐
jected	subcutaneously	in	the	right	flank	of	non‐obese	diabetic/severe	
combined	immunodeficient	(NOD/SCID)	mice	(female,	4‐6	weeks	old)	
at	106	cells/injection.	Once	the	tumour	became	palpable,	the	tumour‐
bearing	mice	were	randomly	assigned	to	a	thiostrepton	group	(5	mg/
kg,	 5	 days/wk,	 intraperitoneal	 injection)	 or	 a	 control	 group	 (DMSO	
vehicle).	Over	a	period	of	4	weeks,	 the	 tumour	sizes	 in	both	groups	
were	measured	weekly	with	standard	calipers.	The	in	vivo	tracking	of	
tumour	growth	was	then	determined	and	presented	as	the	fold	change	
in	 tumour	volume	over	 time.	All	 animal	experiments	were	approved	
by	 the	 Taipei	 Medical	 University	 Animal	 Center	 (Protocol	 number:	
LAC‐2013‐0086).	The	animals	were	humanely	killed	by	cervical	dislo‐
cation	to	minimize	the	suffering.	All	tumour	samples	were	harvested	
for	further	analyses.
3  | RESULTS
3.1 | Identification of thiostrepton as a potential 
anti‐CSC agent using the Connectivity Map database
We	compared	20	different	published	data	sets	 (Table	S1)	and	em‐
ployed	 CSC‐related	 gene	 expression	 profiles	 as	 inputs	 to	 query	
11	 641	 L1000‐based	 gene	 expression	 profiles.	 Thiostrepton	 was	
identified	as	a	candidate	that	could	significantly	reverse	lung	cancer	
gene	 signatures	 (Figure	 1A).	As	 an	 example,	GSE18150	was	 origi‐
nally	generated	from	cells	treated	with	DZNep	by	disrupting	EZH2 
and	 impairing	 CSC	 self‐renewal.29	 Thiostrepton	 profiles,	 including	
treatments	 in	different	cancer	cells	 in	 triplicate,	were	grouped	 to‐
gether	and	used	as	the	input	gene	set	for	GSEA	to	map	the	ranking	
matrix	and	calculate	an	enrichment	score.	The	anti‐CSC	gene	signa‐
ture	from	GSE18150	and	cancer	cells	treated	with	thiostrepton	had	
a	strong	enrichment	score	in	our	11	641	L1000	assays	(normalized	
enrichment	score	=	1.914,	P‐value	<.0001,	Figure	1B).	The	majority	
of	thiostrepton	profiles	had	a	positive	connectivity	score,	and	only	a	
few	had	a	score	of	zero.	This	indicated	a	strong	positive	connectiv‐
ity	between	thiostrepton	and	the	anti‐CSC	gene	signature,	meaning	
thiostrepton	is	a	potential	anti‐CSC	agent.
When	 the	 anti‐CSC	 gene	 signature	 GSE18150	 determined	
by	GEO2R	was	 used	 to	 query	 the	CMap	2.0	 (a	 database	 contain‐
ing	6100	gene	expression	profiles),	thiostrepton	was	ranked	as	the	
top	candidate	(enrichment	score	=	0.797,	P‐value	<.001;	Figure	1B).	
In	results	 from	the	query	of	 the	LINCS	database,	which	contained	
more	 than	 1.3	 million	 gene	 expression	 profiles,	 thiostrepton	 was	
ranked	 as	 the	 22nd	 among	 drugs	 with	 positive	 similarity	 scores	
(score_best4	=	97.368).
The	human	normal	mammary	 stem	cell	 (hNMSC)	gene	expres‐
sion	 signature	 GSE18931,	 a	 CSC	 gene	 signature,	 can	 stratify	 bio‐
logical	and	molecular	features	in	tumours	(Table	S2).	The	degree	of	
cells	expressing	hNMSC	markers	may	reflect	the	CSC	content	of	a	
tumour.30	 L1000	 profiles	with	 a	 negative	 connectivity	 score	 (nor‐
malized	enrichment	score	=	−2.0146;	P‐value	<.0001;	false	discover	
rate	 <0.0001)	 indicated	 that	 thiostrepton	 treatment	 may	 reverse	
gene	signatures	of	GSE18931.	Similarly,	when	GSE18931	was	used	
to	query	the	LINCS	database,	the	results	showed	that	thiostrepton	
had	a	score_best4	of	−93.176	among	the	compounds	with	negative	
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similarity	 scores.	This	 strong	 concordance	 across	different	pertur‐
bagen	databases	 indicated	 that	 thiostrepton	 is	 likely	 to	have	 anti‐
CSC	abilities.
In	 addition,	 our	 GSEA	 showed	 that	 thiostrepton	 has	 signifi‐
cant	connectivity	with	the	anti‐EMT	gene	signature	of	salinomycin	
(GSE17215)	with	specific	toxicity	for	epithelial	CSCs35	(normalized	
enrichment	score	=	1.436;	P‐value	=	.005,	Figure	1C).	Further	val‐
idation	 was	 demonstrated	 by	 the	 up‐regulated	 expression	 of	 E‐
cadherin	 and	 down‐regulated	 expression	 of	 Slug	 and	 vimentin	 in	
thiostrepton‐treated	CL141	cells	(Figure	1D).	Moreover,	treatment	
with	 thiostrepton	not	only	distinctly	 reduced	FOXM1	expression	
but	 also	 reduced	 vimentin	 and	 Slug	 expression	 and	 inhibited	 Src	
and	 AKT	 activation	 in	 CL141	 cells	 in	 a	 dose‐dependent	 manner	
(Figure	1E).
3.2 | Thiostrepton suppresses NSCLC cell growth, 
clonogenicity and migration
Non–small‐cell	 lung	 cancer	 cells	 were	 treated	 with	 thiostrep‐
ton.	Figure	2A,B	shows	that	thiostrepton	suppressed	cellular	vi‐
ability	 and	colony‐forming	ability	 in	a	dose‐dependent	manner.	
The	half‐maximal	inhibitory	concentration	(IC50)	of	thiostrepton	
F I G U R E  1   Identification	of	thiostrepton	as	an	anti‐cancer	stem	cell	agent	using	genomic	approaches.	A,	Flowchart	of	array	analysis	and	
prediction	of	potential	anti‐CSC	agents	in	NSCLC.	B,	Pre‐ranked	GSEA	of	81	gene	expression	profiles	of	thiostrepton	among	the	11	641	
L1000	gene	expression	profiles.	The	ranking	metric	scores	were	connectivity	scores	against	the	anti‐CSC	signature	of	DZNep	(GSE18150).	
The	hits	(black	vertical	lines)	are	thiostrepton	profiles.	C,	The	anti‐EMT	signature	(GSE17215)	of	salinomycin	was	used	to	generate	
connectivity	scores	for	ranking	metric	scores.	D,	A	Western	blotting	assay	indicated	that	thiostrepton	treatment	(2.5	μmol/L)	enhanced	E‐
cadherin	expression	and	reduced	Slug	expression	in	CL141	cells.	E,	Thiostrepton	treatment	reduced	vimentin	and	Slug	expression,	inhibited	
Src	and	AKT	activation	and	reduced	FOXM1	expression	in	a	dose‐dependent	manner	in	CL141	cells
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in	 the	 clonogenic	 assay	was	 approximately	 0.05	μmol/L,	which	
was	distinctly	lower	than	that	of	cytotoxic	effects	(Table	S3).	In	
addition,	 treatment	with	 thiostrepton	 significantly	 reduced	 the	
migration	 capability	 of	 A549,	 CL141,	 CL152	 and	 H1299	 cells	
(Figure	2C).
A	previous	study	demonstrated	enhanced	sphere‐forming	abil‐
ity,	cisplatin	resistance	and	migration	ability	in	CD133+	H460	cells.26 
To	 verify	 the	 potential	 anti‐CSC	 effect	 of	 thiostrepton,	 we	 used	
H460	cells	expressing	GFP	driven	by	a	CD133	promoter	 for	cyto‐
toxicity	analysis.	Both	parental	H460	and	CD133+	H460	cells	were	
then	subjected	to	an	SRB	assay.	We	found	that	the	CD133+	H460	
cells	(IC50	=	1.7	μmol/L)	were	more	sensitive	to	thiostrepton	than	the	
parental	H460	cells	(IC50	=	6.9	μmol/L;	Table	S3).
3.3 | Thiostrepton suppresses CSC properties in 
NSCLC cells
For	in	vitro	validation,	tumour	spheres	of	CL141	cells	were	generated	
under	serum‐free	conditions	and	CSC	properties	were	examined	in	
these	tumour	spheres.	By	using	an	Aldefluor	assay,	we	found	CL141	
tumour	 spheres	 were	 enriched	 with	 ALDH1+	 cells	 (S:	 1.2%)	 com‐
pared	with	their	parental	counterparts	(P:	0.5%,	Figure	3A),	and	the	
relative	ALDH	activity	was	significantly	 increased	 (Figure	3B).	The	
expression	 of	 stem	 cell‐related	markers,	 including	 CD44,	 Oct‐4A,	
Sox2	and	c‐Myc,	was	also	up‐regulated	in	CL141	tumour	sphere	cells	
(Figure	3C).
Thiostrepton	treatment	prominently	suppressed	CL141	tumour	
spheres	formation	in	a	dose‐dependent	manner	(Figure	3D).	This	ob‐
servation	was	supported	by	thiostrepton	treatment	in	both	parental	
cells	and	spheres.	Treatment	with	thiostrepton	reduced	the	expres‐
sion	of	CSC	markers,	including	CD133,	Oct‐4A	and	Nanog,	as	well	as	
suppressed	metastasis‐associated	Src	signalling	(Figure	3E).
Furthermore,	a	stable	CSC‐like	A549‐ON	cells	was	used	to	vali‐
date	the	anti‐CSC	and	anti‐EMT	ability	of	thiostrepton.	Thiostrepton	
treatment	significantly	decreased	expression	of	Oct‐4A	and	Nanog	
and	up‐regulated	expression	of	E‐cadherin	 (Figure	3F),	 supporting	
the	hypothesis	that	thiostrepton	is	a	potential	anti‐CSC	agent.
3.4 | Thiostrepton and gemcitabine synergistically 
suppresses NSCLC tumour sphere formation
Thiostrepton	 in	 combination	 with	 gemcitabine,	 cisplatin,	 pem‐
etrexed	 or	 gefitinib	 reduced	NSCLC	 cell	 viabilities	 synergistically	
(Figure	4A).	The	obtained	average	CI	values	 from	 thiostrepton	 in	
combination	with	gemcitabine,	gefitinib,	cisplatin	and	pemetrexed	
were	0.41	±	0.16,	0.80	±	0.19,	0.91	±	0.25	and	1.04	±	0.30,	respec‐
tively.	This	indicates	that	thiostrepton	plus	gemcitabine	showed	the	
best	synergistic	effect	among	these	combinations.	In	addition,	the	
CI	values	in	different	ratios	(1:1,	1:2,	1:4	and	1:8)	all	showed	syn‐
ergistic	effects	in	the	CL141,	CL152	and	H1299	cells	(Figure	4B).
CD133	and	Oct‐4A,	 the	CSC	markers,	have	been	suggested	as	
protectors	for	cancer	cells	from	apoptosis	induced	by	chemothera‐
peutic	agents.25,26,36	Significantly	 increased	apoptosis‐related	pro‐
teins—cleaved	caspase‐3	and	cleaved	PARP—were	observed	in	cells	
treated	with	 gemcitabine	 plus	 thiostrepton	 (Figure	 4C).	Apoptosis	
induced	 by	 gemcitabine	 plus	 thiostrepton	 was	 more	 significant	
compared	with	 that	 induced	by	gemcitabine	or	 thiostrepton	alone	
(Figure	4C).
F I G U R E  2  Thiostrepton	treatment	suppresses	NSCLC	
tumorigenesis.	Thiostrepton	treatment	significantly	suppressed	
NSCLC	cell	viability	(A)	and	colony	formation	(B)	in	A549,	H1299,	
CL141	and	CL152	cells.	C,	Thiostrepton	inhibited	NSCLC	cell	
migration.	The	bars	indicate	relative	migratory	ability	(left	y‐
axis),	which	is	compared	with	the	vehicle	(control;	0).	Relative	
cell	viability	(right	y‐axis)	is	indicated	by	solid	lines.	These	data	
suggest	that	the	decreased	cell	migration	by	thiostrepton	was	not	
associated	with	the	reduction	of	cell	viability.	**P	<	.01,	***P	<	.001
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Furthermore,	the	combination	of	thiostrepton	and	gemcitabine	
suppressed	 expression	 of	 stemness	markers,	 such	 as	 Sox2,	 β‐cat‐
enin	 and	 EMT	 transcription	 factor	 Slug	 in	 both	CL141	 and	CL152	
cells	(Figure	4D),	indicating	that	the	combination	of	thiostrepton	and	
gemcitabine	suppresses	stemness‐	and	EMT‐related	profiles	in	both	
adenocarcinoma	 and	 squamous	 cell	 carcinoma	 cells.	 This	 finding	
suggests	thiostrepton	could	reduce	cancer	stem‐like	cell	populations	
and	decrease	the	risk	of	distant	metastasis.
We	 also	 characterized	 the	 combination	 treatment	 on	 CL141	
parental	cells	and	tumour	spheres.	Thiostrepton,	with	or	without	
gemcitabine,	 was	 able	 to	 suppress	 CD133	 expression,	 whereas	
gemcitabine	 treatment	 did	 not	 (Figure	 4E).	 Importantly,	 CL141	
spheres	 responded	 to	 a	 lower	 concentration	 of	 thiostrepton	
(1	µmol/L),	 as	 reflected	by	 significantly	 decreased	CD133	 levels	
(Figure	4E).	 In	 the	presence	of	 thiostrepton,	CL141	spheres	also	
responded	 to	 gemcitabine	 at	 a	 lower	 concentration	 and	 under‐
went	 apoptotic	 cell	 death	 as	 reflected	 by	 the	 elevated	 level	 of	
cleavage	of	PARP.
3.5 | Thiostrepton inhibits NSCLC 
tumorigenesis and decreases the proportion of CSC 
in vivo
NOD/SCID	 mice	 that	 received	 daily	 thiostrepton	 treatment	
(n	 =	5)	 exhibited	 a	 significantly	 slower	 tumour	 growth	 rate	 than	
mice	 receiving	 the	 vehicle	 treatment	 (n	 =	 5)	 at	 the	 fifth	 week,	
F I G U R E  3  Thiostrepton	inhibits	cancer	
stem	cell	properties.	A,	Flow	cytometric	
analysis	demonstrated	that	CL141	
spheres	(S)	exhibited	a	higher	percentage	
of	ALDH1+	cells	compared	with	the	
CL141	parental	cells	(P).	B,	Quantitative	
presentation	of	the	relative	ALDH	activity	
in	CL141	spheres	(S)	compared	with	CL141	
parental	cells	(P).	C,	Western	blotting	
assay	indicated	that	CL141	spheres	(S)	
expressed	a	significantly	higher	level	of	
CD133,	CD44,	Oct‐4A	and	Sox2	(CSC	
markers)	as	well	as	β‐catenin	and	c‐Myc	
(oncogenic	markers)	compared	with	their	
parental	counterparts	(P).	D,	Thiostrepton	
suppressed	tumour	sphere	formation	in	
CL141	cells	in	a	dose‐dependent	manner.	
E,	Comparative	western	blotting	assay	of	
parental	cells	(P)	and	spheres	(S)	showed	
that	thiostrepton	treatment	led	to	
decreased	expression	of	CD133,	Oct‐4A,	
Nanog	(CSC	markers)	and	metastasis‐
associated	Src	signalling.	F,	In	the	Oct‐4A/
Nanog	overexpressing	A549	(A549‐ON)	
cells,	thiostrepton	treatment	significantly	
decreased	the	expression	of	both	cancer	
stem	cell	markers,	Oct‐4A	and	Nanog,	and	
increased	E‐cadherin	expression
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as	 demonstrated	 by	 approximately	 2‐fold	 smaller	 in	 tumour	 size	
(Figure	5A).	The	body	weight	of	 the	mice	did	not	change	signifi‐
cantly	 during	 the	 treatment	 period	 (Figure	 5B).	 Photographs	 of	
harvested	 tumour	 samples	 showed	 that	 thiostrepton	 treatment	
significantly	 suppressed	 tumour	 growth	 compared	 with	 control	
counterparts	 (Figure	 5C).	 Further	 analysis	 of	 the	 tumour	 sam‐
ples	 revealed	that	 thiostrepton‐treated	tumours	contained	a	sig‐
nificantly	lower	proportion	of	CD133+	cells	(5.6%)	compared	with	
those	of	the	control	group	(16.1%)	(Figure	5D).
3.6 | Thiostrepton treatment was associated with an 
increase in tumour suppressor miR‐98
MicroRNAs	 have	 been	 extensively	 characterized	 and	 identified	 in	
lung	cancer	and	reportedly	 to	play	an	 important	promoter	or	sup‐
pressor	role,	depending	on	their	 target	genes.37‐39	We	examined	a	
panel	of	microRNAs	in	response	to	thiostrepton	treatment	in	CL141	
cells,	and	the	miR‐98	level	appeared	to	be	elevated	by	approximately	
1.5‐fold	(Figure	6A).	By	comparison,	CL141	parental	cells	contained	
a	 significantly	 higher	 level	 of	 intrinsic	 miR‐98	 than	 their	 sphere	
counterparts	 (Figure	6B).	 The	 level	 of	miR‐98	 rose	 in	 the	wake	of	
thiostrepton	 treatment	 in	 both	 CL141	 parental	 cells	 and	 spheres	
(Figure	6B).
By	 increasing	 miR‐98	 (mimic	 molecules)	 levels,	 Sox2,	 Oct‐4A	
and β‐catenin	 were	 suppressed	 in	 both	 CL141	 and	 CL152	 cells	
(Figure	6C).	This	was	similar	to	the	response	to	thiostrepton	treat‐
ment	 in	 CL141	 cells.	 Based	 on	 the	 decreased	 expression	 of	 Slug,	
EMT	was	considered	 reversed	 (Figure	6C).	These	 findings	 suggest	
that	the	suppression	of	CSC	characteristics	and	EMT	by	thiostrepton	
is	through	up‐regulation	of	tumour	suppressor	miR‐98.
4  | DISCUSSION
In	this	study,	thiostrepton	was	identified	as	a	potential	drug	for	con‐
verting	embryonic	 stem	cell‐like	gene	 signatures	 to	 those	of	 adult	
stem	cell	gene	signatures.	Through	in	vitro	and	in	vivo	experiments,	
we	demonstrated	 that	 thiostrepton	effectively	 inhibited	 lung	CSC	
growth	by	the	suppressing	cancer	stemness	and	expression	of	EMT	
genes.	A	combination	of	thiostrepton	and	gemcitabine	synergistically	
F I G U R E  4  Thiostrepton	combined	with	anti‐cancer	drugs	exhibits	a	synergistic	effect	on	NSCLC	growth.	A,	Fa‐CI	plot	represents	the	CI	
values	and	the	Fa	(fraction	affected,	cytotoxic	effect)	at	different	concentrations	of	thiostrepton	(1.25,	2.5,	and	5	μmol/L)	in	combination	
with	different	chemotherapeutic	drugs	(pemetrexed,	cisplatin,	gemcitabine)	or	gefitinib	(5,	10,	and	20	μmol/L)	for	48	h	in	CL152	cells.	A	
combination	of	thiostrepton	and	gemcitabine	showed	the	highest	synergistic	effect	among	the	combinations.	The	data	were	analysed	
by	CompuSyn	software.	B,	Thiostrepton	was	combined	with	gemcitabine	at	different	dosing	ratios	(1:1,	1:2,	1:4	or	1:8)	in	CL141,	CL152	
and	H1299	cells.	All	combinations	demonstrated	synergistic	anti‐NSCLC	effects.	C,	Western	blotting	assays	for	CL141	cells	treated	with	
thiostrepton	and/or	gemcitabine.	The	combination	of	thiostrepton	and	gemcitabine	effectively	reversed	EMT	and	induced	apoptosis.	
D,	Comparative	Western	blotting	assays	of	CL141	and	CL152	cells	with	treatments	of	thiostrepton,	gemcitabine,	or	thiostrepton	plus	
gemcitabine.	Thiostrepton	treatment	significantly	suppressed	the	expression	of	β‐catenin	(stemness	marker)	and	Slug	(EMT	marker).	When	
combined	with	gemcitabine,	the	suppressive	effect	was	more	pronounced	in	CL152	cells.	E,	Western	blotting	assays	of	CL141	(P)	and	CL141	
spheres	(S)	treated	with	thiostrepton	and/or	gemcitabine.	The	combination	of	thiostrepton	and	gemcitabine	effectively	suppressed	the	
elevated	CD133	expression	in	the	CL141	spheres	and	induced	the	apoptotic	marker‐cleaved	PARP
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suppressed	NSCLC	cell	growth.	This	exploratory	methodology	con‐
necting	disease,	genes	and	chemical	profiles	represents	an	alterna‐
tive	approach	to	the	development	of	novel	therapeutic	agents.
In	 tumour	 sphere	assays,	 increased	EMT	potential	 and	expres‐
sion	 of	 CSC	markers	were	 showed	 in	NSCLC	 cells.	 This	 finding	 is	
in	 agreement	with	 the	 previously	 established	 hypothesis	 that	 en‐
hanced	EMT	potential	 is	positively	associated	with	 the	generation	
of	CSCs.25,40	In	addition,	the	well‐established	CSC	marker,	CD133,	
was	shown	to	be	associated	with	up‐regulated	expression	of	EMT‐
related	genes,	 including	Src	and	Slug.41,42	A	recent	study	reported	
that	FOXM1	directly	and	constitutively	activates	Snail	in	lung	ade‐
nocarcinoma,	 thereby	 promoting	 cancer	metastasis.43	Knockdown	
FOXM1	significantly	suppressed	EMT	progression	as	well	as	tumour	
growth	 and	metastasis.43	 However,	 we	 demonstrated	 that	 thiost‐
repton	 treatment	 did	 not	 inhibit	 Snail	 expression	 but	 strongly	 in‐
hibited	Slug	expression	in	NSCLC	cells.	These	findings	indicate	that	
the	CD133/Src	axis,	in	addition	to	FOXM1,	is	a	potential	therapeutic	
target	 for	 thiostrepton.	 Thiostrepton	 treatment	 not	 only	 inhibited	
CSC	markers	including	CD133,	Oct‐4A	and	Sox2,	but	also	restored	
E‐cadherin	 expression,	 thereby	 reversing	 the	EMT	and	generation	
of	cancer	spheres.	This	finding	further	supports	an	association	be‐
tween	the	EMT	and	CSC.
Ectopic	expression	of	Oct4	and	Nanog	in	lung	cancer	cells	was	
associated	with	a	significant	increase	in	the	percentage	of	CD133+	
cell	 and	mesenchymal	 cell	 populations,	 the	ability	 to	 form	 tumour	
spheres	and	enhanced	drug	resistance.25	To	provide	further	support	
the	contention	 that	 thiostrepton	 is	a	potential	anti‐CSC	agent,	we	
utilized	a	cell	model	that	A549	cells	with	overexpression	of	Oct‐4A/
Nanog	 exhibits	 enhanced	 CSC	 characteristics	 and	 EMT	 potential.	
Thiostrepton	 treatment	 not	 only	 significantly	 suppressed	 ectopic	
expression	of	both	Nanog	and	Oct‐4A	in	the	A549‐ON	cells,	but	also	
markedly	induced	epithelial	marker	E‐cadherin.	These	findings	verify	
our	bioinformatical	prediction	that	thiostrepton	treatment	is	associ‐
ated	with	the	reversal	of	CSC	gene	signatures,	EMT	status	and	CSC	
growth	inhibition.
Thiostrepton	reportedly	enhances	sensitivity	to	platinum	in	vitro	
and in vivo.44	It	has	also	been	reported	that	cisplatin	treatment	sig‐
nificantly	increases	the	proportion	of	CD133+	cells	through	the	Notch	
signal	pathway,	and	CD133+	cells	are	related	to	an	increase	in	cross‐
drug	resistance	to	paclitaxel	and	doxorubicin.26	Therefore,	the	reduc‐
tion	in	CD133+/Oc4‐4A+	cell	populations	in	NSCLC	by	thiostrepton	
treatment	(Figure	3)	provides	further	support	for	a	role	for	thiostrep‐
ton	in	combination	with	chemo‐	and/or	target	therapeutic	agents	in	
preventing	drug	 resistance.	Thiostrepton	 acted	 synergistically	with	
gemcitabine	to	inhibit	lung	cancer	cellular	viability	in	this	study.
The	 GSEA	 results	 of	 thiostrepton	 and	 thiostrepton	 plus	 gem‐
citabine	 with	 concomitant	 enrichment	 scores	 were	 related	 to	
GSE18931	(Table	S2),	which	was	evaluated	for	CSC	gene	signatures	
with	impacts	on	clinical	outcomes	and	the	pathological	features	of	
cancer.30	The	gene	signature	of	thiostrepton	treatment	with	a	pos‐
itive	enrichment	score	was	also	significantly	 related	 to	GSE17215,	
an	anti‐CSC	gene	signature	associated	with	EMT.	Decreased	CSCs	
F I G U R E  5   In	vivo	evaluation	of	anti‐NSCLC	tumour	growth	effect	of	thiostrepton.	A,	H441	tumour‐bearing	NOD/SCID	mice	were	used	
to	evaluate	the	thiostrepton‐mediated	suppressive	effect	on	tumour	growth.	Tumour	burden	(fold	change	in	the	tumour	size)	is	plotted	
over	time.	The	insert	depicts	photographs	of	the	tumour	samples	collected.	Thiostrepton	treatment	(5	mg/kg/d,	5	d/wk,	intraperitoneal	
injection)	inhibited	H441	tumour	growth	compared	with	the	vehicle	control	group	after	4	wk	of	treatment.	**P	<	.01.	B,	The	treatment	did	
not	negatively	affect	the	body	weight	of	the	animals	during	the	experiment	course.	C,	A	photograph	of	tumours	collected	from	mice	in	
both	thiostrepton‐treated	and	vehicle	control	group.	D,	Flow	cytometric	analysis	of	tumours	demonstrated	that	thiostrepton	treatment	
significantly	decreased	the	percentage	of	cells	with	stem	cell	marker	CD133	expression	(presented	by	the	blue	peak	while	the	red	peak	
indicates	the	isotype)
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after	drug	treatment	may	prevent	tumours	from	EMT.	This	finding	
provides	evidence	to	link	the	CSC	state	with	EMT.	Thiostrepton	may	
follow	the	same	path	as	salinomycin	in	reverting	M‐type	cells	back	
to	 E‐type	 cells.35	 Chemotherapy	 combined	with	 thiostrepton	may	
therefore	be	an	alternative	regimen	to	improve	treatment	effective‐
ness	and	prolong	survival	in	patients	with	NSCLC.
Chemotherapy	 is	 still	 a	major	 treatment	 option	 for	 lung	 squa‐
mous	 cell	 carcinoma.	 Thiostrepton	 in	 combination	 with	 gemcit‐
abine	significantly	 inhibited	 lung	squamous	cell	carcinoma	growth.	
However,	cellular	 responses	 towards	different	 treatment	 regimens	
varied	between	adenocarcinoma	and	squamous	cell	carcinoma	cells.	
As	shown	in	Figure	4D,	thiostrepton	alone	significantly	suppressed	
Sox2,	β‐catenin	and	Slug	expression	to	a	greater	extent	in	CL141	cells	
than	 in	CL152	 cells.	While	 gemcitabine	 treatment	 alone	 appeared	
to	suppress	Sox2	expression	more	significantly	 in	CL152	cells,	 the	
suppressive	 effect	 of	 stemness	 and	 EMT	 was	 more	 pronounced	
(Figure	4D).	Our	previous	study	showed	that	thiostrepton	can	sup‐
press	colony	and	sphere	formation	and	trigger	apoptosis	of	colorec‐
tal	cancer	stem	cells	in	HCT‐15	and	HT‐29	cells	as	well	as	EMT	and	
chemo‐resistant	clones	derived	from	them.45	These	findings	indicate	
that	thiostrepton	in	combination	with	chemotherapies	may	improve	
treatment	effectiveness	in	lung	squamous	cell	carcinoma.
In	 this	 study,	 an	 increased	 level	 of	miR‐98	 (a	 tumour	 suppres‐
sor)	was	observed	 in	response	to	thiostrepton	treatment.	Because	
miR‐98	 is	 reportedly	 down‐regulated	 in	 many	 cancer	 types,	 its	
targets,	 such	as	Myc,	Kras	and	Wnt	signalling,	are	generally	onco‐
genic.46‐48	The	exact	targets	for	thiostrepton‐induced	miR‐98	induc‐
tion	in	NSCLC	warrant	further	investigation.
In	 conclusion,	 thiostrepton	 was	 identified	 as	 a	 potential	 CSC	
inhibitor	 for	 lung	 cancer	 using	 an	 integrative	 bioinformatics	 and	
pre‐clinical	 approach.	 In	 combination	 with	 chemotherapeutic	
agents,	 especially	 gemcitabine,	 thiostrepton	 synergistically	 sup‐
pressed	NSCLC	growth	and	tumour	spheres	formation.	An	elevated	
miR‐98	level	was	associated	with	thiostrepton	treatment.	These	pre‐
clinical	evidence	warrants	further	clinical	studies	for	thiostrepton	in	
patients	with	NSCLC.
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